技术与方法 |
|
|
|
|
抗p185 erb B2人鼠嵌合抗体ChAb26转基因小鼠乳腺生物反应器的制备与验证 * |
梁振鑫1,刘芳2,张玮1,刘庆友2,李力1,**() |
1 广西医科大学附属肿瘤医院区域性高发肿瘤早期防治研究教育部重点室验室 南宁 530021 2 广西大学动物科学技术学院 南宁 530004 |
|
The Preparation and Validation of p185 erb B2 Human-mouse Chimeric Antibody ChAb26 Transgenic Mice Mammary Gl and Bioreactor |
LIANG Zhen-xin1,LIU Fang2,ZHANG wei1,LIU Qing-you2,LI Li1,**() |
1 Affiliated Tumor Hospital of Guangxi Medical University,Regional High-Defense Tumor Early Prevention Research Department Key Laboratory of Ministry of Education ,Nanning 530021,China 2 College of Animal Science and Technology, Guangxi University, Nanning 530004, China |
引用本文:
梁振鑫,刘芳,张玮,刘庆友,李力. 抗p185 erb B2人鼠嵌合抗体ChAb26转基因小鼠乳腺生物反应器的制备与验证 *[J]. 中国生物工程杂志, 2019, 39(8): 40-51.
LIANG Zhen-xin,LIU Fang,ZHANG wei,LIU Qing-you,LI Li. The Preparation and Validation of p185 erb B2 Human-mouse Chimeric Antibody ChAb26 Transgenic Mice Mammary Gl and Bioreactor. China Biotechnology, 2019, 39(8): 40-51.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20190806
或
https://manu60.magtech.com.cn/biotech/CN/Y2019/V39/I8/40
|
[1] |
Fanotto V, Ongaro E, Rihawi K , et al. HER-2 inhibition in gastric and colorectal cancers:tangible achievements,novel acquisitions and future perspectives. Oncotarget, 2016,7(42):69060-69074.
|
[2] |
Harbeck N . Advances in targeting HER2-positive breast cancer. Curr Opin Obstet Gynecol, 2018,30(1):55-59.
|
[3] |
Perrier A, Gligorov J, Lefèvre G , et al. The extracellular domain of Her2 in serum as a biomarker of breast cancer. Lab Invest. 2018,98(6):696-707.
|
[4] |
Carvajal-Hausdorf D E, Schalper K A, Bai Y , et al. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. Gynecol Oncol, 2017,145(1):154-158.
|
[5] |
Marano L, Roviello F . The distinctive nature of HER2-positive gastric cancers. Eur J Surg Oncol, 2015,41(3):271-273.
|
[6] |
Wang Y, Zhang S J, Wu F Y , et al. Outcomes of pemetrexed-based chemotherapies in HER2-mutant lung cancers. BMC Cancer, 2018,18(1):326.
|
[7] |
Abdel Azim S, Sprung S, Mutz-Dehbalaie I , et al. L1cam and her2 expression in early endometrioid uterine cancer. Int J Gynecol Pathol, 2017,36(4):356-363.
|
[8] |
Hosseini H, Obradovi? M M, Hoffmann M , et al. Early dissemination seeds metastasis in breast cancer . Nature, 2016 , 640(7634):20785.
|
[9] |
Harper K L, Sosa M S, Entenberg D , et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature, 2016,640(7634):20609.
|
[10] |
Linde N, Casanova-Acebes M, Sosa M S , et al. Macrophages orchestrate breast cancer early dissemination and metastasis. Nat Commun, 2018,9(1):21.
|
[11] |
Stern D F, Heffernan P A, Weinberg R A . P185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol, 1986,6(5):1729-1740.
|
[12] |
Loibl S, Gianni L . HER2-positive breast cancer. Lancet, 2017,389(10087):2415-2429.
|
[13] |
Yanli W, Sihai Z, Liang B , et al. Expression systems and species used for transgenic animal bioreactors. Biomed Res Int, 2013,2013:580463-580469.
|
[14] |
Monzani P S, Adona P R, Ohashi O M . Transgenic bovine as bioreactors:Challenges and perspectives. Bioengineered, 2016 , 7(3):123-131.
|
[15] |
Ma T, Tao J, Yang M , et al. An AANAT/ASMT transgenic animal model constructed with CRISPR/Cas9 system serving as the mammary gland bioreactor to produce melatonin-enriched milk in sheep. J Pineal Res, 2017,63(1):e12406.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|